This article has Open Peer Review reports available.
Fetal and neonatal samples of a precursor surfactant protein B inversely related to gestational age
© Czernik et al.; licensee BioMed Central Ltd. 2013
Received: 3 April 2013
Accepted: 8 October 2013
Published: 10 October 2013
Alveolar–capillary membrane leaks can increase the amount of surfactant protein B (SP-B) in the bloodstream. The purpose of this study was to measure the concentration of C-proSP-B, a SP-B precursor that includes C-terminal domains, in various body fluids of newborn infants and determine its dependence on gestational age.
C-pro-SPB was measured in amniotic fluid and umbilical cord blood at birth, and in peripheral blood and urine on postnatal day 3 in 137 newborn infants with a median birth weight of 2015 g (range, 550–4475 g) and gestational age of 34 weeks (range, 23–42 weeks).
C-proSP-B levels differed more than 100-fold among samples. The levels (median; interquartile range) were highest in peripheral blood (655.6 ng/mL; 419.0-1467.0 ng/mL) and lowest in urine (3.08 ng/mL; 2.96-3.35 ng/mL). C-proSP-B levels in amniotic fluid (314.9 ng/mL; 192.7–603.6 ng/mL) were approximately half of those in peripheral blood. In cord blood C-proSP-B was slightly lower (589.1 ng/mL; 181.2-1129.0 ng/mL) compared with peripheral blood. C-proSP-B levels significantly increased in all the fluids sampled except urine with decreasing gestational age (p < 0.001).
This novel assay allows for the quantitative measurement of C-proSP-B in blood and amniotic fluid. The dependence of C-proSP-B on gestational age may hamper its use for the detection of alveolar leaks in preterm newborns.
Pulmonary surfactant is synthesized by type II pneumocytes and secreted into the airways of the lung beginning at 24 weeks gestation. Its deficiency or dysfunction is the hallmark of respiratory distress syndrome in preterm infants [1, 2]. Pulmonary surfactant consists of a complex of lipids and specific proteins, including surfactant proteins (SP) A, B, C and D. Of these surfactant proteins, SP-B is the only one that is absolutely essential for initiating breathing and life [3–5]. The highly hydrophobic SP-B enhances the absorption of phospholipids onto the air–water interface and optimizes surface tension reduction [6, 7]. SP-B is a relatively small (79 amino acids) hydrophobic polypeptide that is synthesized as a longer, 381-amino-acid precursor that undergoes a complex maturation process along the exocytic pathway of type II pneumocytes . Processing of the SP-B precursor includes proteolytic cleavage of N- and C-terminal domains in at least three different steps. Cleavage of the N-terminal (24–200) and C-terminal (280–381) flanking domains generates the biophysically active, mature SP-B. C-ProSP-B is a transient intermediate in the synthesis of SP-B that does not accumulate in type II pneumocytes .
Although surfactant proteins are normally only found in appreciable amounts in the lung, leakage of SP-A, SP-B and SP-D into the circulation has been reported in a number of respiratory disorders [9–14] and cardiac failure [15–18]. The route by which these proteins enter the circulation is unknown; there is, however, strong evidence that a bidirectional plasma protein flux occurs in the lungs, the magnitude of which depends on disease severity [19, 20]. Jobe et al.  showed that this bidirectional flux from the alveoli increased as gestational age decreased in prematurely delivered, ventilated lambs.
Currently, there are only a few reports describing the measurement of SP-A levels in cord blood and sera from neonates within 24 hours after birth [22, 23]. To date, there are no data regarding C-proSP-B concentrations in the blood of newborn infants. We hypothesized that C-proSP-B could be measured in different samples from newborn infants and that these levels would be correlated with lung maturation. The aim of this exploratory study was to measure C-proSP-B in cord and peripheral blood, amniotic fluid, and urine of preterm and term newborn infants with gestational ages between 24 and 42 weeks.
Patients and protocol
Newborn infants delivered at the Charité University Hospital between October 2009 and May 2011 were enrolled in the study. Infants who died in the first days of life were excluded. The study protocol was approved by the local institutional review board (Ethikkommission der Charité, #EA2/083/09). Written informed consent for sampling was obtained for infants of imminent premature birth before delivery, or on the first day of life in some cases.
Measurement of C-proSP-B in different samples
Samples of amniotic fluid (5 ml) were collected during labor prior to delivery and umbilical cord blood (1 ml) was obtained at birth. Peripheral blood samples were taken within 36 to 72 hours of age through umbilical artery catheter aspiration or venous puncture as part of routine sampling. Urine was collected in plastic bags at the same time. The samples were centrifuged at 7000 rpm (Eppendorf microcentrifuge) for 3 minutes. Cell-free plasma, urine and amniotic fluid were stored at -20°C until C-pro-SPB analysis. The samples were batched and run together after collection was complete. The tests were performed in a single run and in a blinded manner using a new C-proSP-B electrochemiluminescence immunoassay kit employing a Tris(bipyridyl)-ruthenium(II) complex as a label (Roche Diagnostics, Mannheim Germany), as described by the manufacturer. Briefly, biotinylated capture antibody, ruthenium-labeled detection antibody, and sample or standard material (10 μl) were first incubated in a homogeneous phase for 9 minutes at 37°C. Then, streptavidin-coated beads were added and incubated for 9 minutes to allow binding of the formed immune complexes to the microparticles. After the second incubation, the reaction mixture was transferred to the measuring cell, where beads were captured on the electrode surface by a magnet. The measuring cell was washed to remove unbound label and filled with detection buffer containing Tris-propylamine. After applying voltage to the electrode, the emitted chemiluminescence was detected by a photomultiplier. Results were determined using a two-point calibration curve. C-proSP-B values are given as nanograms per milliliter, and were measurable within a range of 0.1 to 3000 ng/mL.
Patient characteristics were described by median and range and compared using the Mann–Whitney rank test. Measured C-ProSP-B values were described by median and interquartile range (IQR) and compared by using Wilcoxon test for paired samples or the Mann–Whitney rank test for independent samples, as appropriate. Spearman rank correlation coefficients (rS) were calculated to investigate the relationship of the C-ProSP-B concentrations between paired samples. A non-linear regression analysis was performed by linearization of nonlinear models to investigate the relationship between C-ProSP-B and gestational age using the Pearson correlation coefficient as a measure of the goodness of fit. Statistical analyses were performed using Statgraphics Centurion® software (Version 16.0, Statpoint Inc., Herndon, Virginia, USA) and MEDCALC (Version 18.104.22.168; MedCalc Software, Mariakerke, Belgium). A p-value < 0.05 was considered statistically significant.
C-proSP-B was measured in 137 patients with a median birth weight of 2240 g (range, 550–4475 g) and a gestational age of 34 weeks (range, 23–42 weeks). 80 (58%) infants were born before 37 gestational weeks (preterm infants) and 17 (12%) infants with a mean gestational age of 28 (24–32) weeks received antenatal steroids. Postnatal mechanical ventilation was necessary for 8 (6%) infants.
C-proSP-B in different samples at which the highest levels were found in the peripheral blood (presented as median and IQR)
Comparisons of different samples
Dependence of C-proSP-B on gestational age
The effect of antenatal steroid treatment and mechanical ventilation on C-proSP-B could not be analyzed in this study due to drop outs in the different samples. The incidence of infants who received antenatal steroid treatment and mechanical ventilation in the four sample groups was very small (≤6 and ≤4 infants, respectively).
The study showed that C-proSP-B can be measured in samples of the peripheral and cord blood, amniotic fluid and urine of newborn infants. However, there were distinct differences among the samples investigated. C-proSP-B concentrations differed more than 100-fold among the samples, and were generally highest in the peripheral blood and lowest in urine. C-proSP-B concentrations in peripheral blood were significantly correlated with those in samples of cord blood and amniotic fluid, but only weakly with those in urine samples. Furthermore, with the exception of urine, C-proSP-B levels increased with decreasing gestational age. How C-proSP-B patterns change with further postnatal development is still unknown.
The dependence of C-proSP-B on maturity may hamper its use in preterm infants as an indicator of capillary–alveolar membrane damage caused, for example, by ventilator-induced lung injury, as shown in adults [24, 25]. Thus, increased levels of C-proSP-B are difficult to interpret. Although non-invasive methods are currently favored [26, 27], intubation and mechanical ventilation are often unavoidable, and the immature lung tissue of these infants is at increased risk of damage. In a review, Takahashi et al.  reported that increased levels of surfactant proteins in body fluids reflect alterations of capillary–alveolar membranes and lung maturity. Determining surfactant proteins in body fluids may aid in monitoring the course of pulmonary diseases, such as pulmonary alveolar proteinosis, respiratory distress syndrome and pneumonia. Awasthi et al.  showed that in premature newborn baboons, the amounts of SP-A and SP-D in lavage fluid were indicators of infection risk in the pathogenesis of neonatal chronic lung disease.
Moreover, Beresford and Shaw described how lower bronchoalveolar lavage SP-B and SP-D concentrations in preterm infants ventilated for respiratory distress syndrome were associated with worse clinical prognoses . In this context, Keller et al.  demonstrated recently in preterm infants that late administration of a surfactant containing SP-B surfactant transiently increases SP-B content in the lung aspirates, possibly leading to improved short- and long-term respiratory outcomes. The diagnostic value of C-proSP-B in newborns in this context is still unknown and will require additional clinical studies. However investigation into the diagnostic value of C-proSP-B as a biomarker should consider that C-proSP-B is highly dependent on gestational age as shown in the present study.
To the best of our knowledge, this is the first study in which C-proSP-B was measured quantitatively in different samples from newborn infants. The four samples investigated are commonly collected for perinatal diagnostics, though it was not possible to obtain all four from every patient. Amniotic fluid can only be obtained non-invasively during delivery. Cord blood is commonly available, though it is difficult to obtain in some patients due to constriction of the vessels. Peripheral blood and urine samples can be collected more reliably, though this requires puncturing a peripheral vessel or using a urine bag, respectively.
It was not surprising that the highest levels of C-proSP-B were found in the peripheral blood. SP-B is a lung-specific protein, so SP-B in amniotic fluid is believed to come directly from the alveolar space, whereas SP-B in blood is thought to have permeated into the circulation from the alveolar space. In this context, SP-B in amniotic fluid transported by fetal breathing movements [31, 32] should directly reflect that in the alveolar space, whereas SP-B in blood is influenced by lung permeability, which increases in direct relationship to the severity of lung damage. The lower concentration of C-proSP-B in amniotic fluid than in peripheral blood may be caused by dilution processes, because the amniotic fluid volume is much greater than the infant’s blood volume. The extremely low concentration measured in urine may reflect impaired transport from blood to urine. The renal clearance of proteins is limited by their molecular mass, hydrophobicity and kidney function, which is related to maturity .
This pilot study has several limitations. Firstly, as discussed above, we could not obtain peripheral and cord blood, amniotic fluid and urine samples from every patient, hampering the comparability of pro-protein levels among different samples. Secondly, ethical considerations prevented us from performing longitudinal measurements; accordingly, we could not assess the pattern of postnatal C-proSP-B development. Thirdly, due to the low number of patients treated und the sample drop out rate, we could not investigate the effect of prenatal steroid treatment and mechanical ventilation on C-proSP-B. Furthermore, we have no C-proSP-B measurements from infants after long-term ventilator support, meaning the effect of lung injury on C-proSP-B could not be quantified. This would need to be addressed in future clinical studies.
C-proSP-B can be measured quantitatively in different samples from newborn infants. The highest concentrations of C-proSP-B were found in peripheral blood. With the exception of urine, C-proSP-B levels increased with decreasing gestational age, a factor that should be considered in the interpretation of elevated levels.
We thank Roche Diagnostics (Mannheim, Germany) for their support. The company had no influence on data interpretation or presentation of results. We are very grateful to Sarah Smithson-Compton, MA for editorial assistance.
- Cogo P, Baritussio A, Rosso F, Gucciardi A, Moretti V, Badon T, et al: Surfactant-associated protein B kinetics in vivo in newborn infants by stable isotopes. Pediatr Res. 2005, 57: 519-522. 10.1203/01.PDR.0000155755.27716.04.View ArticlePubMedGoogle Scholar
- Merrill JD, Ballard RA, Cnaan A, Hibbs AM, Godinez RI, Godinez MH, et al: Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr Res. 2004, 56: 918-926. 10.1203/01.PDR.0000145565.45490.D9.View ArticlePubMedGoogle Scholar
- Serrano AG, Cabre EJ, Perez-Gil J: Identification of a segment in the precursor of pulmonary surfactant protein SP-B, potentially involved in pH-dependent membrane assembly of the protein. Biochim Biophys Acta. 2007, 1768: 1059-1069. 10.1016/j.bbamem.2007.01.010.View ArticlePubMedGoogle Scholar
- Whitsett JA, Nogee LM, Weaver TE, Horowitz AD: Human surfactant protein B: structure, function, regulation, and genetic disease. Physiol Rev. 1995, 75: 749-757.PubMedGoogle Scholar
- Tokieda K, Whitsett JA, Clark JC, Weaver TE, Ikeda K, McConnell KB, et al: Pulmonary dysfunction in neonatal SP-B-deficient mice. Am J Physiol. 1997, 273: L875-L882.PubMedGoogle Scholar
- Walther FJ, Hernandez-Juviel JM, Gordon LM, Sherman MA, Waring AJ: Dimeric surfactant protein B peptide sp-b(1–25) in neonatal and acute respiratory distress syndrome. Exp Lung Res. 2002, 28: 623-640. 10.1080/01902140260426733.View ArticlePubMedGoogle Scholar
- Dhar P, Eck E, Israelachvili JN, Lee DW, Min Y, Ramachandran A, et al: Lipid-protein interactions alter line tensions and domain size distributions in lung surfactant monolayers. Biophys J. 2012, 102: 56-65. 10.1016/j.bpj.2011.11.4007.View ArticlePubMedPubMed CentralGoogle Scholar
- Korimilli A, Gonzales LW, Guttentag SH: Intracellular localization of processing events in human surfactant protein B biosynthesis. J Biol Chem. 2000, 275: 8672-8679. 10.1074/jbc.275.12.8672.View ArticlePubMedGoogle Scholar
- Robertson B, Curstedt T, Herting E, Sun B, Akino T, Schafer KP: Alveolar-to-vascular leakage of surfactant protein A in ventilated immature newborn rabbits. Biol Neonate. 1995, 68: 185-190. 10.1159/000244236.View ArticlePubMedGoogle Scholar
- Russo TA, Bartholomew LA, Davidson BA, Helinski JD, Carlino UB, Knight PR, et al: Total extracellular surfactant is increased but abnormal in a rat model of gram-negative bacterial pneumonia. Am J Physiol Lung Cell Mol Physiol. 2002, 283: L655-L663.View ArticlePubMedGoogle Scholar
- Kuroki Y, Tsutahara S, Shijubo N, Takahashi H, Shiratori M, Hattori A, et al: Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis. 1993, 147: 723-729. 10.1164/ajrccm/147.3.723.View ArticlePubMedGoogle Scholar
- Chida S, Phelps DS, Soll RF, Taeusch HW: Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics. 1991, 88: 84-89.PubMedGoogle Scholar
- Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, et al: Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med. 1995, 152: 1860-1866. 10.1164/ajrccm.152.6.8520747.View ArticlePubMedGoogle Scholar
- Bersten AD, Hunt T, Nicholas TE, Doyle IR: Elevated plasma surfactant protein-B predicts development of acute respiratory distress syndrome in patients with acute respiratory failure. Am J Respir Crit Care Med. 2001, 164: 648-652. 10.1164/ajrccm.164.4.2010111.View ArticlePubMedGoogle Scholar
- Magri D, Brioschi M, Banfi C, Schmid JP, Palermo P, Contini M, et al: Circulating plasma surfactant protein type B as biological marker of alveolar-capillary barrier damage in chronic heart failure. Circ Heart Fail. 2009, 2: 175-180. 10.1161/CIRCHEARTFAILURE.108.819607.View ArticlePubMedGoogle Scholar
- Agostoni P, Banfi C, Brioschi M, Magri D, Sciomer S, Berna G, et al: Surfactant protein B and RAGE increases in the plasma during cardiopulmonary bypass: a pilot study. Eur Respir J. 2011, 37: 841-847. 10.1183/09031936.00045910.View ArticlePubMedGoogle Scholar
- Pascual-Figal DA, Sanchez-Mas J, de la Morena G, Casas T, Garrido IP, Ruiperez JA, et al: Pulmonary surfactant protein B in the peripheral circulation and functional impairment in patients with chronic heart failure. Rev Esp Cardiol. 2009, 62: 136-142. 10.1016/S0300-8932(09)70155-1.View ArticlePubMedGoogle Scholar
- De Pasquale CG, Arnolda LF, Doyle IR, Aylward PE, Russell AE, Bersten AD: Circulating surfactant protein-B levels increase acutely in response to exercise-induced left ventricular dysfunction. Clin Exp Pharmacol Physiol. 2005, 32: 622-627. 10.1111/j.0305-1870.2005.04241.x.View ArticlePubMedGoogle Scholar
- Eisner MD, Parsons P, Matthay MA, Ware L, Greene K: Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax. 2003, 58: 983-988. 10.1136/thorax.58.11.983.View ArticlePubMedPubMed CentralGoogle Scholar
- Doyle IR, Bersten AD, Nicholas TE: Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure. Am J Respir Crit Care Med. 1997, 156: 1217-1229. 10.1164/ajrccm.156.4.9603061.View ArticlePubMedGoogle Scholar
- Jobe A, Jacobs H, Ikegami M, Berry D: Lung protein leaks in ventilated lambs: effects of gestational age. J Appl Physiol. 1985, 58: 1246-1251.PubMedGoogle Scholar
- Cho K, Matsuda T, Okajima S, Matsumoto Y, Sagawa T, Fujimoto S, et al: Prediction of respiratory distress syndrome by the level of pulmonary surfactant protein A in cord blood sera. Biol Neonate. 2000, 77: 83-87. 10.1159/000014198.View ArticlePubMedGoogle Scholar
- Kaneko K, Shimizu H, Arakawa H, Ogawa Y: Pulmonary surfactant protein A in sera for assessing neonatal lung maturation. Early Hum Dev. 2001, 62: 11-21. 10.1016/S0378-3782(00)00133-X.View ArticlePubMedGoogle Scholar
- Pison U, Seeger W, Buchhorn R, Joka T, Brand M, Obertacke U, et al: Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis. 1989, 140: 1033-1039. 10.1164/ajrccm/140.4.1033.View ArticlePubMedGoogle Scholar
- Takahashi H, Sano H, Chiba H, Kuroki Y: Pulmonary surfactant proteins A and D: innate immune functions and biomarkers for lung diseases. Curr Pharm Des. 2006, 12: 589-598. 10.2174/138161206775474387.View ArticlePubMedGoogle Scholar
- Mahmoud RA, Roehr CC, Schmalisch G: Current methods of non-invasive ventilatory support for neonates. Paediatr Respir Rev. 2011, 12: 196-205. 10.1016/j.prrv.2010.12.001.View ArticlePubMedGoogle Scholar
- Ramanathan R: Optimal ventilatory strategies and surfactant to protect the preterm lungs. Neonatology. 2008, 93: 302-308. 10.1159/000121456.View ArticlePubMedGoogle Scholar
- Awasthi S, Coalson JJ, Yoder BA, Crouch E, King RJ: Deficiencies in lung surfactant proteins A and D are associated with lung infection in very premature neonatal baboons. Am J Respir Crit Care Med. 2001, 163: 389-397. 10.1164/ajrccm.163.2.2004168.View ArticlePubMedGoogle Scholar
- Beresford MW, Shaw NJ: Bronchoalveolar lavage surfactant protein a, B, and d concentrations in preterm infants ventilated for respiratory distress syndrome receiving natural and synthetic surfactants. Pediatr Res. 2003, 53: 663-670. 10.1203/01.PDR.0000054653.89527.F8.View ArticlePubMedGoogle Scholar
- Keller RL, Merrill JD, Black DM, Steinhorn RH, Eichenwald EC, Durand DJ, et al: Late administration of surfactant replacement therapy increases surfactant protein-B content: a randomized pilot study. Pediatr Res. 2012, 72: 613-619. 10.1038/pr.2012.136.View ArticlePubMedPubMed CentralGoogle Scholar
- Higuchi M, Hirano H, Gotoh K, Takahashi H, Maki M: Relationship of fetal breathing movement pattern to surfactant phospholipid levels in amniotic fluid and postnatal respiratory complications. Gynecol Obstet Invest. 1991, 31: 217-221. 10.1159/000293162.View ArticlePubMedGoogle Scholar
- Kalache KD, Chaoui R, Marks B, Wauer R, Bollmann R: Does fetal tracheal fluid flow during fetal breathing movements change before the onset of labour?. BJOG. 2002, 109: 514-519. 10.1111/j.1471-0528.2002.01265.x.View ArticlePubMedGoogle Scholar
- Sonntag J, Prankel B, Waltz S: Serum creatinine concentration, urinary creatinine excretion and creatinine clearance during the first 9 weeks in preterm infants with a birth weight below 1500 g. Eur J Pediatr. 1996, 155: 815-819. 10.1007/BF02002914.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2431/13/164/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.